18.05.2014 Views

triple response of Lewis - South West Peninsula Deanery

triple response of Lewis - South West Peninsula Deanery

triple response of Lewis - South West Peninsula Deanery

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Dr Andrea Magides & Dr D I Natusch<br />

<strong>South</strong> Devon Pain Service


Peripheral small unmyelinated nerve fibres<br />

Picture courtesy <strong>of</strong> Astellas Pharma


The <strong>triple</strong> <strong>response</strong> <strong>of</strong> <strong>Lewis</strong> is<br />

a cutaneous <strong>response</strong> that<br />

occurs from firm stroking <strong>of</strong> the<br />

skin, which produces an initial<br />

red line, followed by a flare<br />

around that line, and then<br />

finally a wheal the “<strong>Lewis</strong><br />

Effect”.<br />

The <strong>triple</strong> <strong>response</strong> <strong>of</strong> <strong>Lewis</strong> is<br />

due to the release <strong>of</strong> histamine<br />

and other vasoactive<br />

substances.


picture<br />

A complex inflammatory and humeral cellular “conversation”


Ionotropic Receptor Subtype Ligand<br />

TRP 1,2,A Heat, Capsaicin, H+<br />

(A = noxious cold)<br />

Acid Sensing DRASIC ; ASIC H+<br />

Purine P2X3 ATP<br />

Serotonin 5HT3 SHT<br />

NMDA NR1 glutamate<br />

AMPA iGluRI glutamate<br />

kainate iGluR5 glutamate


Slide courtesy <strong>of</strong> Astellas Pharma


Receptors) Subtype Ligand<br />

Glutamate mGluR1,2/3,5 glutamate<br />

Prostanoids EPI-4,IP PGE2, PGI2<br />

Histamine HI HA<br />

Serotonin 5HTIA, 5HT4,5HT2A 5HT<br />

Bradykinin B1,B2 BK<br />

Cannabinoid CB1-2 anandamide<br />

Tackykinin NK1 Substance P,<br />

Neurokinin A<br />

Opioid Mu, Delta, Kappa Enkephalins


Congenital Pain Insensitivity seen rarely in<br />

humans and animals.<br />

Channelopathies / receptor defects.<br />

Recent studies have identified some families<br />

with genetic defects causing pain syndromes<br />

all <strong>of</strong> which affect peripheral nerve systems<br />

only.


Beggs et al. Molecular Pain 2010


Primary afferents contain excitatory amino acids (glutamate)<br />

and neurotransmitters (substance p). These depolarise AMPA<br />

receptors for a short and predictable time.<br />

Repeated C-Fibre input results in progressive membrane<br />

depolarisation and removal <strong>of</strong> the magnesium block from<br />

NMDA receptors (Windup) mediated by glutamate acting on<br />

NMDA receptors and Substance P on neurokinin receptors.<br />

Fast high density stimulation activates long-term<br />

potentiation. This with windup and secondary hyperalgesia<br />

including the effect <strong>of</strong> wide dynamic neurones use partially<br />

overlapping systems all contribute to central sensitisation.<br />

Intense ongoing stimuli further excite transmission. And cause<br />

activation <strong>of</strong> cFOS genes and changes in cellular protein<br />

expression.<br />

Further excitatory processes involving many types <strong>of</strong><br />

transmitter and messengers occur in the dorsal root ganglia.


Ketamine


Tyr-gly-gly-phe-met<br />

<br />

Tyr-gly-gly-phe-leu<br />

Small penta peptides that are made from precursors-<br />

Proenkephalin<br />

Pro-opiomelanocortin<br />

Prodynorphin<br />

Work on specific receptors – Cause a hyper polarisation<br />

<strong>of</strong> cells as a result <strong>of</strong> calcium influx leading to a<br />

decreased release <strong>of</strong> transmitters and decreased<br />

synaptic activity. Depending on the cell activity this can<br />

have a depressive or an excitatory effect.


Mu (morphine) MOP<br />

Kappa (ketocyclazocine) KOP<br />

Delta (vas deferens) DOP<br />

Nociceptin Orphanin FQ peptide receptor<br />

(NOP)


Classic opioid dose<br />

<strong>response</strong> curves you<br />

have been taught are<br />

not actually based on<br />

pharmacdynamic data<br />

in patients with pain.<br />

Nimmo and Smith 1994


Naturally occurring<br />

phenanthrene derivative<br />

Low lipid solubility and slow<br />

penetration <strong>of</strong> the bloodbrain<br />

barrier<br />

Extensively metabolised by<br />

gut wall and liver to<br />

M3G(70%) and M6G(10%)<br />

and sulphate conjugates<br />

M6G 10-20X more potent<br />

than morphine and is<br />

excreted in urine


„partial agonist‟ at mu opioid<br />

receptor, weak agonist at<br />

delta opioid sites and<br />

antagonist kappa opioid<br />

receptor.<br />

Intrinsic anti-tolerance<br />

effects


Buprenorphine has a ceiling effect for analgesia.<br />

*Buprenorphine induces a ceiling in respiratory depression but not analgesia.<br />

Dahan A et al, BJA 2006,96(5):627-32<br />

No evidence <strong>of</strong> a plateau (0.1-10mg) in humans.<br />

<br />

Buprenorphine is a partial agonist and will antagonise the effects <strong>of</strong> other<br />

opioids<br />

Persistent blockade <strong>of</strong> Mu receptor does not occur and subsequent use <strong>of</strong><br />

other opioids is not affected in the acute or chronic situation.<br />

<br />

Lack <strong>of</strong> Naloxone reversibility <strong>of</strong> respiratory depression.<br />

Buprenorphine induced respiratory depression can be reversed by naloxone<br />

albeit in higher doses. Budd K. Old dog- new matrix BJA 2003; 90(6) 722-<br />

724


Weak agonist at all opioid<br />

receptors (MOP 20X)<br />

Inhibits neuronal reuptake <strong>of</strong><br />

norepinephrine.<br />

Potentiates release <strong>of</strong> serotonin<br />

and causes descending<br />

inhibition <strong>of</strong> nociception.<br />

Metabolised by demethylation<br />

Several metabolites –one active<br />

(o-desmethyltramadol)<br />

Mu-opioid receptor agonist<br />

and norepinephrine<br />

reuptake inhibition<br />

Main metabolic pathway for<br />

elimination <strong>of</strong> tapentadol is<br />

phase II glucuronidation<br />

No active metabolites<br />

Low potential for drug-drug<br />

interaction<br />

TRAMADOL<br />

TAPENTADOL


Watkins Trends Pharcol 2009


Ensure other treatment options have been maximised.<br />

Consider opioid therapy as an adjunct ; sole opioid therapy is rarely<br />

successful.<br />

Use goal directed therapy; set limits and goals and agree to these.<br />

Unless pain is occasional base regime on long acting opioids and avoid<br />

breakthrough medication.<br />

Be prepared to wean and discontinue if treatment goals are not met.<br />

Ballentyne and LaForge K S. Opioid Dependence and addiction during<br />

opioid treatment <strong>of</strong> chronic pain.<br />

Pain 2007 ; 129 : 235-255<br />

Pain Clinic –negotiating firm limits


“The brain is an organ whose function is<br />

to make meaning”<br />

Dr Dorothy Rowe, Psychologist


Subconscious<br />

„detection system‟<br />

„messaging system‟ to central processing in the spinal cord<br />

and brain<br />

„message modulation‟ system<br />

automatic neural & endocrine changes and <strong>response</strong>s<br />

The Brain has the ability to processes information and at<br />

some level this becomes part <strong>of</strong> consciousness and has<br />

to make sense.


The gate control theory explains how counter stimulation<br />

helps pain but it was not sophisticated enough to fully<br />

explain central sensitisation but did recognise the key role<br />

<strong>of</strong> modulation by the brain and higher centres.


Mantyh and Tracey 2007<br />

Insular Cortex : ?? “ouch it hurts<br />

but is it an important bit and<br />

what is the magnitude?”<br />

Anterior Cingulate Cortex<br />

?? “Alert : Something going on<br />

here!”<br />

Somatosensory Cortex<br />

?? “Its this bit”<br />

Thalamic Nuclei : ?? Information<br />

processing.<br />

Pre frontal cortex<br />

?? “How does this relate to me in<br />

the outside world??”


DIRECTION TO PAIN OR PLEASURE<br />

DEFINED BY Emotional STATE (Valence<br />

-German) as in „AMBIVALENCE „ i.e.<br />

emotions in 2 directions – C.Jung)<br />

Think about “tickling” to see how<br />

context and attentional focus can<br />

alter skin sensitivity and define<br />

pleasure or pain in <strong>response</strong> to non<br />

harmful stimulus.


Social pain activates the same<br />

Neuromatrix pattern as<br />

nociceptive input…<br />

Eisenberger, Science 302(5643): 290-2


Petrovic et al Science 2002


Moulin et al Lancet 1996


Before and After : Torbay Pain Management Program


Hurt = harm (fear avoidance behaviours)<br />

<br />

Movement & re-injury (kinesiophobia).<br />

<br />

Worry - Catastrophisation<br />

Can interfere with movement and activity


Cognitive Behavioural Therapy in depression – Aaron Beck noticed<br />

depressed patients have depressive thinking and selectively access<br />

depressive memories. Uses Socratic Questioning techniques as a way<br />

<strong>of</strong> challenging automatic negative thinking alongside behavioural<br />

experiments. As effective as medication in mild / moderate<br />

depression. CBT has been adapted for Pain and may contain elements<br />

<strong>of</strong> relaxation / self hypnosis.<br />

<br />

Acceptance and Commitment Therapy : learning techniques for<br />

distress tolerance and acceptance <strong>of</strong> symptoms. Developing<br />

techniques <strong>of</strong> cognitive diffusion – „notice thoughts but don‟t act on<br />

them‟ and mindfulness meditation- developed from Zen Buddhism by<br />

Cabbot-Zin.<br />

<br />

Compassion Focused Therapy – aims to teach compassion skills and<br />

self soothing techniques to people who are not kind to themselves<br />

and have a poor self esteem leading to behavioural problems.<br />

<br />

Most Clinical Psychologists use elements <strong>of</strong> different therapies in<br />

individual therapy or groups (Pain Management Programmes)


CONGNITIVE - BEHAVIOURAL Bio-psycho-social MODEL Model OF PAIN<br />

Pain management unit


Stratified Care in Chronic Pain<br />

Pain, disability<br />

And high distress<br />

Pain, disability<br />

and low Distress<br />

Chronic Pain, low disability low distress


How your brain works!


Receptor Specificity<br />

Noradrenaline<br />

Serotonin<br />

NA+5HT<br />

"NARIS"<br />

Reboxetine<br />

"SSRI"<br />

Fluoxetine<br />

"SNRI"<br />

Venlafaxine<br />

"NASSA"<br />

Mirtirzapine<br />

"RIMA"<br />

Moclobemide<br />

"MAOI"<br />

"TRICYCLICS"<br />

Amitriptyline<br />

Nortriptyline<br />

L<strong>of</strong>epramine


Tricyclic Antidepressant<br />

Its metabolite Nortriptyline is equipotent but has<br />

fewer cholinergic and sedative side effects.<br />

TCA seem to be equipotent but differ in terms <strong>of</strong><br />

muscarinic side effects and safety in overdosage<br />

(L<strong>of</strong>epramine safer and fewer side effects than<br />

most TCA‟s).<br />

TCA‟s in dosing studies have maximal effect for<br />

pain around 70mg.


Duloxetine<br />

Serotonin Noradrenaline Reuptake Inhibitor.<br />

<br />

It is effective for depression and generalised anxiety<br />

disorder.<br />

NICE Guidelines for Neuropathic Pain – first line<br />

treatment for neuropathic pain in diabetes.


ANTICONVULSANTS<br />

Enhance inhibition <strong>of</strong><br />

GABA<br />

VALPROATE<br />

CLONAZEPAM<br />

Stabalise cell<br />

membranes<br />

PHENYTOIN<br />

CARBAMAZEPINE<br />

Bind to calcium or<br />

sodium channels<br />

GABAPENTIN<br />

PREGABALIN


Gabapentin and Pregabalin do not act on GABA receptor but<br />

A2 Delta receptor ( Calcium Channels).<br />

Effective in Neuropathic Pain and Pregabalin is a first line drug for<br />

neuropathic pain according to NICE Guidelines.<br />

Perioperative gabapentinoids (gabapentin/ pregabalin) reduce<br />

postoperative pain and opioid requirements (U) and reduce the<br />

incidence <strong>of</strong> vomiting, pruritus and urinary retention, but increase the<br />

risk <strong>of</strong> sedation (N) (Level I).<br />

Perioperative use <strong>of</strong> gabapentin after mastectomy reduced the incidence <strong>of</strong><br />

neuropathic pain at 6 months postoperatively, from 25% in the placebo to<br />

5% (Fassoulaki et al, 2002 Level II).


Pictures from a variety <strong>of</strong> sources including Dr Howard Fields with<br />

thanks, <strong>South</strong> Devon Pain Archive and Wikipedia unless referenced and<br />

information for Acute Pain, The Scientific Evidence,<br />

Faculty <strong>of</strong> Pain Medicine ANZACA 3 rd Edition

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!